Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
DUBLIN, Ireland, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three and six months ended June 30, 2019 and recent corporate highlights.
“Nabriva has made significant advances in the second quarter as we prepare for the upcoming PDUFA date for both the intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP),” said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics. “Additionally, in collaboration with one of our third party manufacturers, we had a productive meeting with the U.S. Food and Drug Administration (FDA) related to the CONTEPO Complete Response Letter (CRL), and hope to provide an update to investors in the weeks ahead with the goal of bringing this important treatment to patients as quickly as possible.”
RECENT CORPORATE AND DEVELOPMENT HIGHLIGHTS
Three Months Ended June 30, 2019 and 2018
Six Months Ended June 30, 2019 and 2018
Please refer to our Annual Report on Forms 10-K for the fiscal year ended December 31, 2018 and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019, which are filed with the U.S. Securities and Exchange Commission, for additional information regarding our business and financial results.
About Nabriva Therapeutics plc
Consolidated Balance Sheets
Consolidated Statements of Operations